Pfizer seeking FDA OK for COVID-19 vaccine booster dose
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 25/08/2021 (1864 days ago), so information in it may no longer be current.
Pfizer is seeking U.S. approval of a booster dose of its two-shot COVID-19 vaccine.
The drugmaker said Wednesday that it has started the application process for a third dose of its vaccine for everyone ages 16 and older. The company said it will complete the application with the Food and Drug Administration by the end of this week.
The FDA earlier this month said transplant recipients or others with weakened immune systems can get an extra dose of Pfizer or Moderna vaccines. Then last week, U.S. health officials announced plans to give COVID-19 booster shots to all Americans to shore up their protection amid the surging delta variant of the coronavirus.
That plan drew criticism from scientists at the World Health Organization, who noted that poor countries are not getting enough vaccine for their initial rounds of shots.
Pfizer’s vaccine, jointly developed with Germany’s BioNTech, received full FDA approval earlier this week, also for those ages 16 and older. It had been given to that age group under an emergency use authorization, which is still the case for those ages 12 to 15.
More than 200 million doses of the Pfizer vaccine have been administered in the U.S. — and hundreds of millions more worldwide — since it got the green light in December.
The three vaccines used in the U.S. made by Pfizer, Moderna and Johnson & Johnson are still preventing hospitalizations and deaths from COVID-19. But the vaccines don’t appear quite as strong against the highly contagious delta variant as they were against earlier versions of the virus.
The U.S. booster plan calls for an extra dose eight months after people get their second shot of the Pfizer or Moderna vaccine.
Also on Wednesday, J&J said people who received a booster for its single-shot vaccine saw a big jump in virus-fighting antibodies. The drugmaker plans to talk to regulators about its booster.
Moderna is expected to do the same. It said Wednesday that it had completed its application to the FDA for full approval of its two-dose vaccine.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Advertisement Advertise With Us
